

Amendments to the Claims

1. (Currently amended) A method of treating ~~Use of papaverine-like vasodilator for the production of a pharmaceutical composition for the treatment of an~~ ophthalmological dysfunction ~~dysfunctions~~ which is ~~are~~ linked to circulatory disturbances of the eye or which can ~~are to~~ be attributed to circulatory disturbances of the eye, comprising administering a pharmaceutical composition comprising a papaverine-like vasodialator, wherein said ~~the~~ pharmaceutical composition is administered ~~to be applied~~ topically to said ~~the~~ eye.
2. (Currently amended) The method according to ~~Use as set forth in claim 1~~ wherein characterised ~~in that~~ the papaverine-like vasodilator is selected from the group consisting of which consists of papaverine, ethaverine, moxaverine, elziverine, their pharmacologically compatible salts and mixtures thereof.
3. (Currently amended) The method according to claim 1 ~~Use as set forth in one of the preceding claims characterised in that~~ wherein the ophthalmological dysfunction ~~dysfunctions~~ is ~~are~~ selected from the group consisting of which consists of glaucoma and an ophthalmological dysfunction ~~dysfunctions~~ linked to diabetes, ~~for example neovascularisation glaucoma, and diabetic retinopathy.~~

4. (Currently amended) ~~The method according to claim 1 Use as set forth in one of claims 1 through 3 characterised in that~~ wherein the pharmaceutical composition is in ~~a~~ the form selected from the group consisting of eye drops, eye ointments, eye spray, eye tablet, gel, suspension, emulsion, powder and ~~or~~ granules.
5. (Currently amended) ~~The method according to claim 1 Use as set forth in one of the preceding claims characterised in that~~ wherein the pharmaceutical composition ~~additionally~~ includes a viscosity regulator, wherein the viscosity regulator has a viscosity-increasing action.
6. (Currently amended) ~~The method according to Use as set forth in claim 5 characterised in that~~ wherein the viscosity regulator is selected from the group ~~which consists~~ consisting of chondroitin sulfate, polyacrylamide, polyacrylic acid, polyacrylic resins, polyethylene glycol, cellulose derivatives, polyvinyl alcohol, polyvinyl pyrrolidone, hyaluronic acid, hyaluronates and mixtures thereof.
7. (Currently amended) A pharmaceutical composition which includes a papaverine-like vasodilator and a pharmacologically compatible viscosity regulator, wherein the papaverine-like vasodilator is selected from the group ~~which consists~~ consisting of moxaverine, its pharmacologically compatible salts and mixtures

thereof, and wherein the viscosity regulator is selected from the group ~~which~~
~~consists~~ consisting of chondroitin sulfate, polyacrylamide, polyacrylic acid,
polyacrylic resins, polyethylene glycol, cellulose derivatives, polyvinyl alcohol,
polyvinyl pyrrolidone, hyaluronic acid, hyaluronates and mixtures thereof.

8. (Currently amended) A pharmaceutical composition as set forth in claim 7 wherein
~~characterised in that~~ the pharmaceutical composition is in a ~~the~~ form selected from
the group consisting of eye drops, eye ointments, eye spray, eye tablet, gel,
suspension, emulsion, powder and ~~or~~ granules.
9. (New) The method according to claim 3 wherein said ophthalmological dysfunction
linked to diabetes is selected from the group consisting of neovascularisation
glaucoma and diabetic retinopathy.